Symbio
Symbio is a client-focused, global Clinical Research Organization (CRO) specializing in dermatology, inflammatory diseases, aesthetics, and other therapeutic areas. They provide comprehensive services including project management, data management, medical monitoring, biostatistics, site selection, monitoring, medical writing, and subject recruitment. With offices in the United States and Europe, Symbio has extensive experience managing clinical trials across phases I–IV and medical device trials, with a focus on delivering tailored solutions and clinical excellence. They have completed over 650 clinical studies and maintain strong relationships with research sites to streamline recruitment and reduce enrollment timelines. Symbio is committed to advancing dermatological and related therapeutic research, forming long-term partnerships with sponsors, and providing submission-ready data and reports.
Industries
Nr. of Employees
medium (51-250)
Symbio
Port Jefferson, Ohio, United States, North America
Products
StackPack™ 40
A compact and efficient zero emission hydrogen fuel cell system for all passenger cars segments and light commercial vehicle applications.
StackPack™ 150
Compact and high-performing hydrogen fuel cell system for trucks, designed for integration into existing vehicle engine bays or wheelbase.
StackPack™ 300
Compact and high-performing hydrogen fuel cell system for trucks, designed for integration into existing vehicle engine bays or wheelbase, suitable for mid-range to heavy-duty vehicles including EMS vehicles.
H2MOTIVE STACKPACK™ 75
The H2Motive StackPack™ 75 is a compact 75 kW fuel cell system designed for performance, high efficiency, and low heat rejection, suitable for automotive applications including light and medium duty trucks, buses, and off-road vehicles.
StackPack™ 75 hydrogen fuel cell system
A 75-kW optimized fuel cell system tailored for intensive mobility, designed for heavy-duty use in urban and intercity buses and coaches, light and medium trucks, as well as off-road handling and construction equipment.
400 kW StackPack™ fuel cell system
A regional 8-class vehicle retrofitted with a powerful 400 kW Symbio fuel cell replacing a 15-liter diesel powertrain, designed for zero-emission heavy-duty mobility with unprecedented range and performance capabilities.
StackPack™ 40
A compact and efficient zero emission hydrogen fuel cell system for all passenger cars segments and light commercial vehicle applications.
StackPack™ 150
Compact and high-performing hydrogen fuel cell system for trucks, designed for integration into existing vehicle engine bays or wheelbase.
StackPack™ 300
Compact and high-performing hydrogen fuel cell system for trucks, designed for integration into existing vehicle engine bays or wheelbase, suitable for mid-range to heavy-duty vehicles including EMS vehicles.
H2MOTIVE STACKPACK™ 75
The H2Motive StackPack™ 75 is a compact 75 kW fuel cell system designed for performance, high efficiency, and low heat rejection, suitable for automotive applications including light and medium duty trucks, buses, and off-road vehicles.
StackPack™ 75 hydrogen fuel cell system
A 75-kW optimized fuel cell system tailored for intensive mobility, designed for heavy-duty use in urban and intercity buses and coaches, light and medium trucks, as well as off-road handling and construction equipment.
400 kW StackPack™ fuel cell system
A regional 8-class vehicle retrofitted with a powerful 400 kW Symbio fuel cell replacing a 15-liter diesel powertrain, designed for zero-emission heavy-duty mobility with unprecedented range and performance capabilities.
Services
Protocol development, project management, monitoring, medical monitoring, data management, biostatistics, and medical writing for Phase I–IV and medical device studies.
Database design, validation, electronic case report form capture, query management, and rapid topline reporting post-database lock.
Statistical analysis planning, development of statistical analysis plans, DoE application, and generation of study tables/listings/figures.
Turnkey topical product design, formulation development, analytical method development and validation, stability studies, GMP manufacture of clinical supplies, clinical packaging, labeling and distribution.
Regulatory strategy and document preparation to support regional submissions, including eCTD-ready clinical study reports and compliance guidance for device investigations.
Site identification and selection using an established investigator/site database, plus a dedicated recruitment team to accelerate enrollment.
Protocol development, project management, monitoring, medical monitoring, data management, biostatistics, and medical writing for Phase I–IV and medical device studies.
Database design, validation, electronic case report form capture, query management, and rapid topline reporting post-database lock.
Statistical analysis planning, development of statistical analysis plans, DoE application, and generation of study tables/listings/figures.
Turnkey topical product design, formulation development, analytical method development and validation, stability studies, GMP manufacture of clinical supplies, clinical packaging, labeling and distribution.
Regulatory strategy and document preparation to support regional submissions, including eCTD-ready clinical study reports and compliance guidance for device investigations.
Site identification and selection using an established investigator/site database, plus a dedicated recruitment team to accelerate enrollment.
Expertise Areas
- Clinical trial management
- Dermatology-focused clinical research
- Topical product formulation and clinical supply manufacturing
- Biostatistics and advanced trial design
Key Technologies
- Electronic data capture (EDC)
- CDISC-compliant datasets
- eCTD clinical study report preparation
- Quality by Design (QbD) principles
News & Updates
Our colleague, Shrutimita Pokhariyal, will represent Symbio as both a Moderator and Speaker at the upcoming 6th International Conference on Dermatology and Cosmetology (IDC2025). Shrutimita will join an inspiring lineup of global experts dedicated to advancing skin science and clinical innovation. On June 2nd, from 3:40 PM to 4:00 PM CET, she will deliver a compelling presentation titled “Design of Experiment in Injectable Trials” and reflects her deep commitment to scientific excellence and thoughtful study design. With her deep expertise in clinical development and commitment to scientific excellence, Shrutimita’s contribution underscores Symbio’s continued dedication to innovation, quality, and thought leadership in dermatological research. We look forward to her insights sparking meaningful dialogue and collaboration at IDC2025.
Symbio is thrilled to announce and share the recent press release from Jasper Therapeutics. We are incredibly proud to have been the CRO partner for this successful study. This achievement marks a significant milestone in our collaboration and commitment to advancing innovative therapies for the treatment of Urticaria and other mast cell-mediated diseases. Read full press release, “Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria”
Our colleague, Shrutimita Pokhariyal, will represent Symbio as both a Moderator and Speaker at the upcoming 6th International Conference on Dermatology and Cosmetology (IDC2025). Shrutimita will join an inspiring lineup of global experts dedicated to advancing skin science and clinical innovation. On June 2nd, from 3:40 PM to 4:00 PM CET, she will deliver a compelling presentation titled “Design of Experiment in Injectable Trials” and reflects her deep commitment to scientific excellence and thoughtful study design. With her deep expertise in clinical development and commitment to scientific excellence, Shrutimita’s contribution underscores Symbio’s continued dedication to innovation, quality, and thought leadership in dermatological research. We look forward to her insights sparking meaningful dialogue and collaboration at IDC2025.
Symbio is thrilled to announce and share the recent press release from Jasper Therapeutics. We are incredibly proud to have been the CRO partner for this successful study. This achievement marks a significant milestone in our collaboration and commitment to advancing innovative therapies for the treatment of Urticaria and other mast cell-mediated diseases. Read full press release, “Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria”